Subscribe - Individual

Subscribe - Biotech Premium (Corporate)

Categories

lachlan conference
September 3rd, 2024

What's Next for Clinuvel Pharmaceuticals?

Over the last seven years, Clinuvel Pharmaceuticals (CUV: $14.95) has generated around $330 million in sales from its pharmaceutical product Scenesse for the treatment of EPP. The compound annual growth rate in sales over the last six years has been 42% and the company has been profitable for the last seven years.

island pharma
August 1st, 2024

Island Pharmaceuticals Update

Island Pharmaceuticals' (ILA: $0.066) lead drug candidate, ISLA-101, was first investigated as an oncology drug by Janssen (Johnson & Johnson). Executive Chairman of Island, Paul MacLeman, said that whilst its ability to kill cancer cells was poor, its safety profile was good and well established. ISLA-101 has been assessed in 45 clinical studies to date.

Screenshot 20240822 100332
August 1st, 2024

Summit Coverage: Neuren Pharmaceuticals Outlines Path Forward for NNZ-2591

Opening the first session of the 18th Bioshares Biotech Summit, Neuren Pharmaceuticals' CEO Jon Pilcher spoke of Neuren's success with trofinetide and NNZ-2591, and the commercial options on the table.

neuren angelman
August 1st, 2024

Neuren Pharmaceuticals Reports Positive Results in Third Indication - Angelman Syndrome

Neuren Pharmaceuticals (NEU: $15.57) announced last week top-line Phase II results for NNZ-2591 in Angelman syndrome (AS). NNZ-2591 is a synthetic peptide that maintains the bioavailability of IGF-1 which promotes synaptic connections in the brain. It is the follow-on compound from trofinetide (DAYBUE) which has been approved and is being sold by Acadia Pharmaceuticals.

AROAmain
August 1st, 2024

Aroa Biosurgery - Moving to Cashflow Positive

Aroa Biosurgery (ARX: $0.52) expects to become cashflow positive in the second half of its financial year, which ends 31 March. In the June quarter the company increased receipts by 17.7% to NZ$17.8 million.

BOTANIX SOF
July 10th, 2024

Botanix Raises $70 million with Sofdra FDA Approval

Botanix Pharmaceuticals (BOT: $0.32) has received FDA approval for Sofdra, a prescription medicine for primary axillary hyperhidrosis (PAH), or excessive underarm sweating. It is the first novel chemical entity approved for this indication.

island bioc
July 10th, 2024

Island Pharmaceuticals to In-License New Asset

Island pharmaceuticals (ILA: $0.066) has signed a non-binding term sheet with antiviral drug developer BioCryst to acquire rights to the compound galidesivir for the treatment of a number of dangerous viruses, including Ebola, Zika and Marburg viruses.

CUV Parkinsons
July 10th, 2024

Clinuvel Pharmaceuticals Continues Expansion of Portfolio into Parkinson's Disease

Clinuvel Pharmaceuticals (CUV: $15.51) is continuing to expand the applications for its core therapeutic, afamelanotide (Scenesse for the treatment of EPP). In preclinical models it has been shown that afamelanotide can have a positive impact on neurological conditions, including Parkinson's disease.

cogstate lilly
July 10th, 2024

Donanemab Approved for Alzheimer's Disease; Positive News for Cogstate

Eli Lilly has received FDA approval for donanemab (Kisunla) for the treatment of early-stage Alzheimer's disease. It joins Leqembi from Eisai/Biogen as the first effective, disease modifying treatments for the disease.

radiopharm
July 10th, 2024

Radiopharm to Raise $70 Million Following Transformational Lantheus Deal

Radiopharm Theranostics (RAD: $0.043), a radiopharmaceutical therapeutic-diagnostic company focusing on a range of cancers, has announced an institutional placement of $70 million.

neuren pitt hopkins
June 13th, 2024

Neuren Pharmaceuticals: Positive Phase II Results in Second Study with NNZ-2591

Neuren Pharmaceuticals (NEU: $19.02) announced top-line results for its phase II trial of drug candidate NNZ-2591 in 16 patients with Pitt-Hopkins Syndrome (PTHS).

anteris
June 13th, 2024

Anteris Technologies to Seek Nasdaq Listing Ahead of Registration Study

At this year's AGM held recently, the chairman of Anteris Technologies (AVR: $19.05) John Seaberg said that after 45 years of working in the cardiovascular field, he has never seen a device with as much potential as the DurAVR aortic valve.

dimerix taiba
June 12th, 2024

Second Licensing Deal for Dimerix; Share Price Up 65%

Dimerix (DXB: $0.56) announced an exclusive license agreement with Taiba to commercialise DMX-200 in seven Middle Eastern countries.

blinklab_HJB
May 19th, 2024

Blinklab Partners with Autism Foundation for Pre-Registration Study

Blinklab (BB1: $0.382) which listed on the ASX last month at $0.20, may have easily gone down the VC funding route, with interest at the same time from the US venture capital sector.

 

Screenshot 20240523 105635
April 19th, 2024

IPO Preview – Blinklab

Company: Blinklab

Issue Price: $0.20

Funds to be raised: $7 million

ASX code: BB1

Lead Manager: Westar Capital (not underwritten)

Offer closes: 21 March 2024

Expected listing date: 4 April 2024

Market capitalisation on listing: $20 million

Screenshot 20240201 112927
January 4th, 2024

Top Six Picks for 2024 (Dimerix; ASX = DXB)

Dimerix - Interim Data Assessment in Mid-March

neuren p2 topline results
January 4th, 2024

Impressive Results from Neuren's NNZ-2591 Phase II Clinical Trial in Phelan- McDermid Syndrome

Last month, Neuren Pharmaceuticals (NEU; $24.65) announced impressive top-line data from its Phase II trial of NNZ-2591 conducted in 18 patients with Phelan-McDermid Syndrome (PMS).

Pages